Menu
 
Research menu
Jump to menu

Publications:  Dr Tania Maffucci

Crescente M, Armstrong PC, Kirkby NS, Edin ML, Chan MV, Lih FB, Jiao J, Maffucci T et al.(2020). Profiling the eicosanoid networks that underlie the anti- and pro-thrombotic effects of aspirin. The FASEB Journal
10.1096/fj.202000312R
Patel A, Garcia LF, Mannella V, Gammon L, Borg TM, Maffucci T, Scatolini M, Chiorino G et al.(2020). Targeting p63 Upregulation Abrogates Resistance to MAPK Inhibitors in Melanoma. Cancer research vol. 80, (12) 2676-2688.
10.1158/0008-5472.CAN-19-3230
Cisse O, Quraishi M, Gulluni F, Guffanti F, Mavrommati I, Suthanthirakumaran M, Oh LCR, Schlatter JN et al.(2019). Downregulation of class II phosphoinositide 3-kinase PI3K-C2β delays cell division and potentiates the effect of docetaxel on cancer cell growth. J Exp Clin Cancer Res vol. 38, (1)
10.1186/s13046-019-1472-9
https://qmro.qmul.ac.uk/xmlui/handle/123456789/63733
Mannella V, Bergamaschi D, Harwood C, Maffucci T (2019). Targeting selective phosphoinositide-3-kinase isoforms as a novel strategy in cutaneous squamous cell carcinoma. BRITISH JOURNAL OF DERMATOLOGY. vol. 180, E213-E213.
Emmanouilidi A, Fyffe CA, Ferro R, Edling CE, Capone E, Sestito S, Rapposelli S, Lattanzio R et al.(2019). Preclinical validation of 3-phosphoinositide-dependent protein kinase 1 inhibition in pancreatic cancer. J Exp Clin Cancer Res vol. 38, (1)
10.1186/s13046-019-1191-2
https://qmro.qmul.ac.uk/xmlui/handle/123456789/58605
Ferro R, Adamska A, Lattanzio R, Mavrommati I, Edling CE, Arifin SA, Fyffe CA, Sala G et al.(2018). GPR55 signalling promotes proliferation of pancreatic cancer cells and tumour growth in mice, and its inhibition increases effects of gemcitabine. Oncogene vol. 37, (49) 6368-6382.
10.1038/s41388-018-0390-1
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43263
Arifin SA, Paternoster S, Carlessi R, Casari I, Ekberg JH, Maffucci T, Newsholme P, Rosenkilde MM et al.(2018). Oleoyl-lysophosphatidylinositol enhances glucagon-like peptide-1 secretion from enteroendocrine L-cells through GPR119. Biochim Biophys Acta vol. 1863, (9) 1132-1141.
10.1016/j.bbalip.2018.06.007
https://qmro.qmul.ac.uk/xmlui/handle/123456789/43084
Janus JM, O¿Shaughnessy RFL, Harwood CA, Maffucci T(2017). Phosphoinositide 3-kinase-dependent signalling pathways in cutaneous squamous cell carcinomas. Cancers vol. 9, (7)
10.3390/cancers9070086
https://qmro.qmul.ac.uk/xmlui/handle/123456789/25106
Raimondi C, Calleja V, Ferro R, Fantin A, Riley AM, Potter BVL, Brennan CH, Maffucci T et al.(2016). A Small Molecule Inhibitor of PDK1/PLCγ1 Interaction Blocks Breast and Melanoma Cancer Cell Invasion. Scientific Reports vol. 6, 26142-26142.
10.1038/srep26142
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12725
Chikh A, Ferro R, Abbott JJ, Piñeiro R, Buus R, Iezzi M, Ricci F, Bergamaschi D et al.(2016). Class II phosphoinositide 3-kinase C2β regulates a novel signaling pathway involved in breast cancer progression. Oncotarget vol. 7, (14) 18325-18345.
10.18632/oncotarget.7761
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12294
Mavrommati I, Cisse O, Falasca M, Maffucci T(2016). Novel roles for class II Phosphoinositide 3-Kinase C2β in signalling pathways involved in prostate cancer cell invasion. Scientific Reports vol. 6,
10.1038/srep23277
https://qmro.qmul.ac.uk/xmlui/handle/123456789/12198
Maffucci T, Falasca M(2014). New insight into the intracellular roles of class II phosphoinositide 3-kinases. Biochem Soc Trans vol. 42, (5) 1378-1382.
10.1042/BST20140140
Falasca M, Casari I, Maffucci T(2014). Cancer chemoprevention with nuts. J Natl Cancer Inst vol. 106, (9)
10.1093/jnci/dju238
Edling CE, Selvaggi F, Ghonaim R, Maffucci T, Falasca M(2014). Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. Cancer Biol Ther vol. 15, (5) 524-532.
10.4161/cbt.28018
Franco I, Gulluni F, Campa CC, Costa C, Margaria JP, Ciraolo E, Martini M, Monteyne D et al.(2014). PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function. Dev Cell vol. 28, (6) 647-658.
10.1016/j.devcel.2014.01.022
Maffucci T, Falasca M(2014). Analysis, regulation, and roles of endosomal phosphoinositides. Methods Enzymol vol. 535, 75-91.
10.1016/B978-0-12-397925-4.00005-5
Mazza S, Maffucci T(2014). Autophagy and pancreatic β-cells. Vitam Horm vol. 95, 145-164.
10.1016/B978-0-12-800174-5.00006-5
Falasca M, Maffucci T(2014). Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. Front Physiol vol. 5,
10.3389/fphys.2014.00391
Mazza S, Maffucci T, Falasca M(2013). Investigating the mechanisms of activation and action of phosphoinositide 3-kinase C2 alpha in pancreatic beta cells. DIABETIC MEDICINE vol. 30, 32-32.
Tibolla G, Piñeiro R, Chiozzotto D, Mavrommati I, Wheeler AP, Norata GD, Catapano AL, Maffucci T et al.(2013). Class II phosphoinositide 3-kinases contribute to endothelial cells morphogenesis. PLoS One vol. 8, (1)
10.1371/journal.pone.0053808
https://qmro.qmul.ac.uk/xmlui/handle/123456789/5207
Raimondi C, Chikh A, Wheeler AP, Maffucci T, Falasca M(2012). A novel regulatory mechanism links PLCγ1 to PDK1. J Cell Sci vol. 125, (Pt 13) 3153-3163.
10.1242/jcs.100511
Falasca M, Maffucci T(2012). Regulation and cellular functions of class II phosphoinositide 3-kinases. Biochem J vol. 443, (3) 587-601.
10.1042/BJ20120008
Maffucci T(2012). An introduction to phosphoinositides. Curr Top Microbiol Immunol vol. 362, 1-42.
10.1007/978-94-007-5025-8_1
Mavrommati I, Maffucci T(2011). mTOR Inhibitors: Facing New Challenges Ahead. Curr Med Chem
10.2174/092986711796011247
Dominguez V, Raimondi C, Somanath S, Bugliani M, Loder MK, Edling CE, Divecha N, da Silva-Xavier G et al.(2011). Class II phosphoinositide 3-kinase regulates exocytosis of insulin granules in pancreatic beta cells. J Biol Chem vol. 286, (6) 4216-4225.
10.1074/jbc.M110.200295
Piñeiro R, Maffucci T, Falasca M(2011). The putative cannabinoid receptor GPR55 defines a novel autocrine loop in cancer cell proliferation. Oncogene vol. 30, (2) 142-152.
10.1038/onc.2010.417
Falasca M, Raimondi C, Maffucci T(2011). Boyden chamber. Methods Mol Biol vol. 769, 87-95.
10.1007/978-1-61779-207-6_7
Mazza S, Maffucci T(2011). Class II phosphoinositide 3-kinase C2alpha: what we learned so far. Int J Biochem Mol Biol vol. 2, (2) 168-182.
Mavrommati I, Maffucci T(2011). mTOR inhibitors: facing new challenges ahead. Curr Med Chem vol. 18, (18) 2743-2762.
10.2174/092986711796011247
Edling CE, Selvaggi F, Buus R, Maffucci T, Di Sebastiano P, Friess H, Innocenti P, Kocher HM et al.(2010). Key role of phosphoinositide 3-kinase class IB in pancreatic cancer. Clin Cancer Res vol. 16, (20) 4928-4937.
10.1158/1078-0432.CCR-10-1210
Persaud SJ, Arden C, Bergsten P, Bone AJ, Brown J, Dunmore S, Harrison M, Hauge-Evans A et al. (2010). Pseudoislets as primary islet replacements for research. Islets report no. Islets 2(4),
10.4161/isl.2.4.12557
Persaud SJ, Arden C, Bergsten P, Bone AJ, Brown J, Dunmore S, Harrison M, Hauge-Evans A et al.(2010). Pseudoislets as primary islet replacements for research: report on a symposium at King's College London, London UK. Islets vol. 2, (4) 236-239.
10.4161/isl.2.4.12557
Falasca M, Chiozzotto D, Godage HY, Mazzoletti M, Riley AM, Previdi S, Potter BVL, Broggini M et al.(2010). A novel inhibitor of the PI3K/Akt pathway based on the structure of inositol 1,3,4,5,6-pentakisphosphate. Br J Cancer vol. 102, (1) 104-114.
10.1038/sj.bjc.6605408
Raimondi C, Maffucci T, Potter BVI, Falasca M (2010). A novel and selective PDK1 inhibitor reduces breast cancer cell invasion and tumour growth. BREAST CANCER RESEARCH. vol. 12, S3-S3.
10.1186/bcr2500
Abbott J, Pineiro R, Oliviero MA, Lattanzio R, Piantelli M, Bilancio A, Maffucci T, Falasca M (2010). Phosphoinositide 3-kinase class II beta is a novel target in breast cancer therapy. BREAST CANCER RESEARCH. vol. 12, S5-S5.
10.1186/bcr2507
Maffucci T, Raimondi C, Abu-Hayyeh S, Dominguez V, Sala G, Zachary I, Falasca M(2009). A phosphoinositide 3-kinase/phospholipase Cgamma1 pathway regulates fibroblast growth factor-induced capillary tube formation. PLoS One vol. 4, (12)
10.1371/journal.pone.0008285
Falasca M, Maffucci T(2009). Rethinking phosphatidylinositol 3-monophosphate. Biochim Biophys Acta vol. 1793, (12) 1795-1803.
10.1016/j.bbamcr.2009.10.003
Sala G, Dituri F, Raimondi C, Previdi S, Maffucci T, Mazzoletti M, Rossi C, Iezzi M et al.(2008). Phospholipase Cgamma1 is required for metastasis development and progression. Cancer Res vol. 68, (24) 10187-10196.
10.1158/0008-5472.CAN-08-1181
Falasca M, Hughes WE, Dominguez V, Sala G, Fostira F, Fang MQ, Cazzolli R, Shepherd PR et al.(2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. J Biol Chem vol. 282, (38) 28226-28236.
10.1074/jbc.M704357200
Falasca M, MAFFUCCI T, Fostira F, Sala G, Dominguez V, Hughes WE, James DE, Fang MQ et al.(2007). The role of phosphoinositide 3-kinase C2alpha in insulin signaling. Journal of Biological Chemistry vol. 282, (38) 28226-28236.
10.1074/jbc.M704357200
Maffucci T, Falasca M (2007). Phosphoinositide 3-kinase-dependent regulation of phospholipase Cgamma. Biochem Soc Trans. vol. 35, 229-230.
10.1042/BST0350229
Falasca M, Maffucci T (2007). Role of class II phosphoinositide 3-kinase in cell signalling. Biochem Soc Trans. vol. 35, 211-214.
10.1042/BST0350211
Falasca M, Maffucci T(2006). Emerging roles of phosphatidylinositol 3-monophosphate as a dynamic lipid second messenger. Arch Physiol Biochem vol. 112, (4-5) 274-284.
10.1080/13813450601094664
Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C et al.(2005). Inhibition of the phosphatidylinositol 3-kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. Cancer Res vol. 65, (18) 8339-8349.
10.1158/0008-5472.CAN-05-0121
Maffucci T, Cooke FT, Foster FM, Traer CJ, Fry MJ, Falasca M(2005). Class II phosphoinositide 3-kinase defines a novel signaling pathway in cell migration. J Cell Biol vol. 169, (5) 789-799.
10.1083/jcb.200408005
(2004). 40th EASD Annual Meeting of the European Association for the Study of Diabetes : Munich, Germany, 5-9 September 2004. Diabetologia vol. 47, (Suppl 1) A1-A464.
10.1007/BF03375463
Falasca M, Maffucci T (2004). Phosphatidylinositol-3-phosphate, a new crucial player in insulin signalling, is generated via a TC10-mediated phosphoinositide 3-kinase C2alpha activation. DIABETOLOGIA. vol. 47, A68-A69.
Piccolo E, Vignati S, Maffucci T, Innominato PF, Riley AM, Potter BVL, Pandolfi PP, Broggini M et al.(2004). Inositol pentakisphosphate promotes apoptosis through the PI 3-K/Akt pathway. Oncogene vol. 23, (9) 1754-1765.
10.1038/sj.onc.1207296
Maffucci T, Brancaccio A, Piccolo E, Stein RC, Falasca M(2003). Insulin induces phosphatidylinositol-3-phosphate formation through TC10 activation. EMBO J vol. 22, (16) 4178-4189.
10.1093/emboj/cdg402
Maffucci T, Razzini G, Ingrosso A, Chen H, Iacobelli S, Sciacchitano S, Quon MJ, Falasca M(2003). Role of pleckstrin homology domain in regulating membrane targeting and metabolic function of insulin receptor substrate 3. Mol Endocrinol vol. 17, (8) 1568-1579.
10.1210/me.2001-0211
Piccolo E, Innominato PF, Mariggio MA, Maffucci T, Iacobelli S, Falasca M(2002). The mechanism involved in the regulation of phospholipase Cgamma1 activity in cell migration. Oncogene vol. 21, (42) 6520-6529.
10.1038/sj.onc.1205821
Marra P, Maffucci T, Daniele T, Tullio GD, Ikehara Y, Chan EK, Luini A, Beznoussenko G et al.(2001). The GM130 and GRASP65 Golgi proteins cycle through and define a subdomain of the intermediate compartment. Nat Cell Biol vol. 3, (12) 1101-1113.
10.1038/ncb1201-1101
Marra P, Maffucci T, Daniele T, Di Tullio G, Ikehara Y, Chan EKL, Luini A, Mironov A et al.(2001). The Golgi matrix proteins GM130 and GRASP65 cycle through a novel subdomain of the intermediate compartment. MOL BIOL CELL vol. 12, 208A-208A.
Innominato PF, Mariggio' MA, Piccolo E, Maffucci T, Iacobelli S, Falasca M(2001). The mechanism involved in the regulation of PLC gamma 1 activity in cell migration. CLIN CANCER RES vol. 7, (11) 3780S-3780S.
Maffucci T, Falasca M(2001). Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide-protein co-operative mechanism. FEBS Lett vol. 506, (3) 173-179.
10.1016/s0014-5793(01)02909-x
Return to top